Bell Potter expects FY24 to be a strong year for Neuren Pharmaceuticals despite a miss on the 1Q24 Daybue sales. Management pre-flagged weaker trading forDec/Jan as holiday months.Daybue sales are forecast to improve. Guidance was confirmed at US$370-$420m and 862 US patients were on Daybue at the start of May.Although flat on the February update, net patients have been trending higher in the last 6 weeks and persistence of 58% is meeting the broker's expectations.Due to a slight downgrade in the analyst's revenue forecasts the target price is lowered to $26.50 from $27.Unchanged Buy rating.
Share Price, page-10074
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.82 |
Change
-0.200(1.05%) |
Mkt cap ! $2.403B | |||
| Open | High | Low | Value | Volume |
| $18.96 | $19.06 | $18.72 | $7.172M | 380.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 8015 | $18.82 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.83 | 114 | 1 |
View Market Depth
| Last trade - 16.10pm 12/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$18.82 |
Change
-0.200 ( 0.02 %) |
||||
| Open | High | Low | Volume | ||
| $18.95 | $19.02 | $18.72 | 92995 | ||
| Last updated 15.59pm 12/06/2024 ? | |||||
| NEU (ASX) Chart |